Skip to content

Study · Randomized controlled trial · 2004

4 results

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.

Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB

International journal of impotence research1 Apr 2004Cited by 58 (Europe PMC)

PMID14999221 (opens in a new tab)DOI10.1038/sj.ijir.3901200 (opens in a new tab)PepBankPUB-14999221
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy males, subcutaneous PT‑141 at doses of 0.3 to 10 mg gave a statistically significant erectile response at doses above 1.0 mg.

    In plain wordsIn healthy men, injected PT‑141 caused a clear erection response at doses above 1.0 mg.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseErectile response in healthy males (RigiScan)
    Study

    n: not reported in source

    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    >1.0 mg (tested 0.3 to 10 mg) · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Doses ranging from 0.3 to 10 mg were administered to healthy male subjects, resulting in a statistically significant erectile response at doses greater than 1.0 mg.
    1 context sentence
    Summary · context
    PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects and to patients with erectile dysfunction (ED) who report an inadequate response to Viagra.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In men with erectile dysfunction and inadequate response to Viagra, 4 mg subcutaneous PT‑141 induced a statistically significant erectile response in a crossover design with placebo.

    In plain wordsIn men with erectile dysfunction who responded poorly to Viagra, 4 mg injected PT‑141 caused a clear erection response compared with placebo.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseErectile response in ED patients with inadequate Viagra response
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    4 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The erectile response induced by PT-141 was statistically significant at both doses.
    2 context sentences
    Summary · context
    ED patients were treated with placebo, 4 or 6 mg PT-141 in a crossover design in the presence of VSS.
    Summary · context
    PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects and to patients with erectile dysfunction (ED) who report an inadequate response to Viagra.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In men with erectile dysfunction and inadequate response to Viagra, 6 mg subcutaneous PT‑141 induced a statistically significant erectile response in a crossover design with placebo.

    In plain wordsIn men with erectile dysfunction who responded poorly to Viagra, 6 mg injected PT‑141 caused a clear erection response compared with placebo.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    IncreaseErectile response in ED patients with inadequate Viagra response
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    6 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The erectile response induced by PT-141 was statistically significant at both doses.
    2 context sentences
    Summary · context
    ED patients were treated with placebo, 4 or 6 mg PT-141 in a crossover design in the presence of VSS.
    Summary · context
    PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects and to patients with erectile dysfunction (ED) who report an inadequate response to Viagra.
  4. 04HumanRandomized controlled trialSafety outcome

    Subcutaneous PT‑141 was reported as safe and well tolerated in both studies.

    In plain wordsInjected PT‑141 was reported as safe and well tolerated in both studies.

    Peptide
    Bremelanotide (PT-141)
    Outcome
    Not applicableOverall safety and tolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    PT-141 was safe and well tolerated in both studies.
    1 context sentence
    Summary · context
    PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following subcutaneous administration to healthy male subjects and to patients with erectile dysfunction (ED) who report an inadequate response to Viagra.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.